View Older Stories View More Recent Stories

Jul 8, 2025 07:39AM Bernstein Reiterates Outperform Rating on Regeneron Pharma (REGN)
Jul 7, 2025 09:45AM JPMorgan Reiterates Overweight Rating on Regeneron Pharma (REGN)
Jul 3, 2025 09:08AM TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN)
Jul 2, 2025 11:01AM Regeneron (REGN) Reports Lynozyfic Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
Jul 2, 2025 10:00AM These 30 global stocks offer tactical and structural upside, says RBC
Jun 25, 2025 02:24PM Regeneron the purchaser of Abeona Therapeutics (ABEO) FDA priority review voucher
Jun 20, 2025 05:00AM Regeneron (REGN) Announces Dupixent Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid
Jun 13, 2025 04:25PM 23andMe (MEHCQ) Reaches Agreement for Sale of Business to TTAM Research Institute
Jun 9, 2025 11:09AM Regeneron (REGN) Executive: 23andMe Auction Process Was Recently Reopened and is "Fairly Complicated" - Goldman Sachs Conference
Jun 9, 2025 05:08AM Regeneron Pharma (REGN) PT Lowered to $800 at JPMorgan
Jun 5, 2025 06:01AM Regeneron Pharma (REGN) PT Lowered to $560 at UBS
Jun 4, 2025 05:09AM RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)
Jun 3, 2025 09:29AM RBC Capital: 'What's Regeneron Pharma's (REGN) Best Next Move'
Jun 3, 2025 08:18AM UBS Reiterates Neutral Rating on Regeneron Pharma (REGN)
Jun 2, 2025 09:36AM RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)
Jun 2, 2025 09:09AM Regeneron Pharma (REGN) PT Lowered at Bernstein Following a 'Disappointing Result'
Jun 2, 2025 08:45AM TD Cowen on Regeneron Pharma (REGN): 'LIBTAYO Could Become the Standard of Care'
Jun 2, 2025 08:28AM Truist on Regeneron Pharma (REGN): 'We Could See Stock Trading Sideways Near-Term'
Jun 2, 2025 08:10AM BMO Capital Comments on Regeneron Pharma (REGN): 'COURAGE Data/Obesity License Move REGN Forward'
Jun 2, 2025 07:38AM Regeneron Pharma (REGN) PT Lowered at BMO Capital as 'Updated Model Reflects Conservatism'
Jun 2, 2025 07:07AM Regeneron (REGN) Announces In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
Jun 2, 2025 07:00AM Regeneron (REGN) Reports Interim Results from Ongoing Phase 2 COURAGE Trial
May 30, 2025 12:38PM RBC Capital Downgrades Regeneron Pharma (REGN) to Sector Perform
May 30, 2025 10:12AM Raymond James Reiterates Market Perform Rating on Regeneron Pharma (REGN)
May 30, 2025 10:04AM Guggenheim Reiterates Buy Rating on Regeneron Pharma (REGN)
May 30, 2025 09:27AM Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)
May 30, 2025 09:21AM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
May 30, 2025 08:39AM Oppenheimer Reiterates Outperform Rating on Regeneron Pharma (REGN)
May 30, 2025 06:57AM Regeneron (REGN) Reports Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
May 30, 2025 06:48AM Morgan Stanley Reiterates Overweight Rating on Regeneron Pharma (REGN)
May 29, 2025 09:17AM RBC Capital Previews Regeneron Pharma (REGN): 'Deep Dive Suggests Plenty Of Reasons For Optimism'
May 27, 2025 08:42AM RBC Capital: Regeneron Pharma (REGN) Could Soar on Eylea Spin
May 24, 2025 10:00PM What can get the U.S. large-cap pharma sector to work?
May 22, 2025 05:06PM Regeneron (REGN) announces initial results from Phase 1b of linvoseltamab
May 19, 2025 07:06AM Regeneron (REGN) to Acquire 23andMe in Court-Supervised Sale
May 15, 2025 02:04PM Regeneron (REGN) Prevails over Amgen (AMGN) in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
May 14, 2025 05:01AM Citi Upgrades Regeneron Pharma (REGN) to Buy
May 1, 2025 09:35AM Regeneron (REGN) updates data from oncology and hematology portfolio
Apr 30, 2025 09:39AM Cantor Fitzgerald Reiterates Overweight Rating on Regeneron Pharma (REGN)
Apr 29, 2025 06:32AM Regeneron (REGN) Misses Q1 EPS by 26c
Apr 28, 2025 07:02AM Regeneron (REGN) Announces Lynozyfic Approved in the EU for the Treatment of Relapsed/Refractory Multiple Myeloma
Apr 23, 2025 06:05AM Regeneron Pharma (REGN) PT Lowered to $975 at Truist Securities
Apr 22, 2025 08:09AM Cantor Fitzgerald Reiterates Overweight Rating on Regeneron Pharma (REGN)
Apr 22, 2025 07:23AM Cantor Fitzgerald Assumes Regeneron Pharma (REGN) at Overweight
Apr 21, 2025 10:40AM CFRA Downgrades ABB LTD (ABBN:SW) (ABB) to Hold
Apr 17, 2025 07:03AM Regeneron (REGN): EYLEA HD Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema
Apr 12, 2025 04:00AM Biotech sector Q1 earnings preview from RBC Capital Markets
Apr 10, 2025 07:10AM Regeneron Pharma (REGN) PT Lowered to $940 at Guggenheim
Apr 10, 2025 05:32AM Bernstein Recommends Three US Biotech Stocks Amid 'Heightened Regulatory Uncertainty'
Apr 3, 2025 06:29AM Regeneron Pharma (REGN) PT Lowered to $979 at Bernstein Amid 'Eylea Headwinds'
View More Recent Stories View Older Stories